[HTML][HTML] Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
[PDF][PDF] Evaluation of infliximab/tocilizumab versus tocilizumab among COVID‑19 patients with cytokine storm syndrome
NM Sarhan, AE Abou Warda, HSG Ibrahim… - Scientific …, 2023 - scienceopen.com
Results Baseline patients' characteristics. A total of 153 hospitalized COVID-19 patients
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
NM Sarhan, AEA Warda, HSG Ibrahim… - Scientific …, 2023 - europepmc.org
Results Baseline patients' characteristics. A total of 153 hospitalized COVID-19 patients
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
[PDF][PDF] Evaluation of infliximab/tocilizumab versus tocilizumab among COVID‑19 patients with cytokine storm syndrome
NM Sarhan, AE Abou Warda, HSG Ibrahim… - Scientific Reports, 2023 - d-nb.info
Results Baseline patients' characteristics. A total of 153 hospitalized COVID-19 patients
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
NM Sarhan, AEA Warda, HSG Ibrahim… - Scientific …, 2023 - search.ebscohost.com
Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
NM Sarhan, AEA Warda, HSG Ibrahim… - Scientific …, 2023 - ui.adsabs.harvard.edu
Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
NM Sarha, AEA Warda, HSG Ibrahim, MF Schaalan… - 2023 - cabidigitallibrary.org
Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
[PDF][PDF] Evaluation of infliximab/tocilizumab versus tocilizumab among COVID‑19 patients with cytokine storm syndrome
NM Sarhan, AE Abou Warda, HSG Ibrahim… - Scientific …, 2023 - researchgate.net
Results Baseline patients' characteristics. A total of 153 hospitalized COVID-19 patients
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
were enrolled in the study. Of these, 70 patients received treatment with tocilizumab, 43 …
[HTML][HTML] Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
NM Sarhan, AE Abou Warda, HSG Ibrahim… - Scientific …, 2023 - ncbi.nlm.nih.gov
Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
NM Sarhan, AE Abou Warda, HSG Ibrahim… - Scientific …, 2023 - pubmed.ncbi.nlm.nih.gov
Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies
as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A …
as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A …